This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight new therapeutic options for acute and chronic hyperkalemia. The expert faculty, led by Dr. Charles V. Pollack, Jr., will first provide an introduction and state of the science of hyperkalemia, including risk assessment and disease burden. Recent trial data of both emerged and emerging agents for the treatment of acute and chronic hyperkalemia will be reviewed, and clinical relevance debated through an interactive panel format. The expert faculty will conclude with a review of the role of the interprofessional team in personalized medicine to improve outcomes and quality of life for patients with acute and chronic hyperkalemia.
Cardiologists, residents, internists, nurse practitioners, nurses and other healthcare professionals involved in the management of patients with hyperkalemia
- Assess hyperkalemia risk and disease burden in patients with underlying diseases such as heart failure, diabetes, hypertension, and chronic kidney disease
- Review the recent clinical trial data for the treatment of acute and chronic hyperkalemia to inform clinical decision making
- Improve collaboration among the healthcare team to develop optimal individual treatment strategies for patients with hyperkalemia
Matthew R. Weir, MD
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Charles V. Pollack Jr., MD||Grant/Research Support: AstraZeneca Pharmaceuticals|
|Javed Butler, MD
|Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.|
|Debbie Castner, NP||Speaker’s Bureau: AstraZeneca Pharmaceuticals|
|Matthew R. Weir, MD||Consultant/Advisor: Akebia Therapeutics Inc.; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Janssen Scientific Affairs LLC.; MSD Pharma; Relypsa Inc.; Vifor Pharma|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; John Fanikos, RPh, MBA; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 1.50 CNE Contact Hour, including 1.50 pharmacotherapeutic contact hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (JA4008190-0000-19-009-H01-P).
This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1.Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].